Investigational drug · Phase 2
MKP10241
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 2 Diabetes Mellitus (T2DM), Food Effect, Safety and Tolerability.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MKP10241"
First trial start
2025
Aug 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MKP10241", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus (T2DM)
- Food Effect
- Safety and Tolerability
- Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MKP10241" as an intervention, largest first.
Mankind Pharma LimitedIndustry
NCT07098663 · 68 participants (planned) · Start Aug 12, 2025 · Primary completion Jan 19, 2026
Drug: MKP10241; Placebo · For: Type 2 Diabetes Mellitus (T2DM); Food Effect; Safety and Tolerability and 1 more
Sites: Bayswater, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders.
Rai SK, Patil RI, Ali S, et al. · J Med Chem 2025
Also in development for Type 2 Diabetes Mellitus (T2DM)
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- MWN109 1Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 2Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 3Phase 35 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- BGM0504 AdministeredPhase 32 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes Mellitus (T2DM)
- AD-233APhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233BPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233CPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.